SK DISCOVERY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44,950 KRW | -0.11% |
|
+4.90% | +14.67% |
| Sales 2022 | 8,717B 6.34B 528B | Sales 2023 | 8,939B 6.5B 542B | Capitalization | 758B 551M 45.89B |
|---|---|---|---|---|---|
| Net income 2022 | 427B 311M 25.89B | Net income 2023 | 191B 139M 11.57B | EV / Sales 2022 | 0.23 x |
| Net Debt 2022 | 1,452B 1.06B 87.96B | Net Debt 2023 | 2,190B 1.59B 133B | EV / Sales 2023 | 0.33 x |
| P/E ratio 2022 |
1.5
x | P/E ratio 2023 |
4.04
x | Employees | 48 |
| Yield 2022 |
5.62% | Yield 2023 |
4.34% | Free-Float | 44.1% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.11% | ||
| 1 week | +4.90% | ||
| Current month | +1.70% | ||
| 1 month | +0.45% | ||
| 3 months | +21.65% | ||
| 6 months | +23.15% | ||
| Current year | +14.67% |
1 week
43 900.00
45 350.00
1 month
41 700.0047 000.00
Current year
35 950.0047 750.00
1 year
31 950.0047 750.00
3 years
28 400.0058 700.00
5 years
15 400.0091 600.00
10 years
15 400.00195 971.37
| Managers | Title | Age | Since |
|---|---|---|---|
Cheol Kim
CEO | Chief Executive Officer | 62 | 08/18/08 |
Chan-Joong Park
CEO | Chief Executive Officer | 59 | 08/18/08 |
Chang-Won Chey
CEO | Chief Executive Officer | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Won Chey
CEO | Chief Executive Officer | 59 | - |
Jae-Yong Song
BRD | Director/Board Member | 60 | - |
Chan-Joong Park
CEO | Chief Executive Officer | 59 | 08/18/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 44,950 | -0.11% | 11,085 |
| 25/24/25 | 45,000 | +0.22% | 19,151 |
| 24/24/24 | 44,900 | +1.13% | 14,882 |
| 23/24/23 | 44,400 | +0.45% | 14,633 |
| 22/24/22 | 44,200 | +3.15% | 17,924 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
SK Discovery Co Ltd, formerly SK Chemicals Co Ltd, is a Korea-based company mainly engaged in the manufacture and distribution of chemicals. The Company operates its business through three segments. The Gas segment is engaged in importing, storing and distributing liquefied petroleum gas (LPG). The Life Sciences segment manufactures and sells products such as blood circulation improvers, vaccines, and blood products. The Investment segment operates businesses such as subsidiaries management and new business investment.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +14.67% | 624M | |
| -5.24% | 5.86B | |
| 0.00% | 4.55B | |
| -12.67% | 3.91B | |
| -0.14% | 3.56B | |
| +23.40% | 3.23B | |
| +8.47% | 1.95B | |
| +11.60% | 1.6B | |
| +1.01% | 1.38B | |
| +0.07% | 1.1B |
- Stock Market
- Equities
- A006120 Stock
